Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cellectis S.A. CLLS
$1.74
-$0.07 (-3.86%)
На 18:00, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
102735538.00000000
-
week52high
4.10
-
week52low
1.77
-
Revenue
19171000
-
P/E TTM
-1
-
Beta
2.06106800
-
EPS
-1.90000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 04:00
Описание компании
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Goldman Sachs | Sell | Sell | 24 мая 2022 г. |
| Baird | Outperform | Neutral | 18 мая 2022 г. |
| Barclays | Overweight | Overweight | 13 мая 2022 г. |
| Wells Fargo | Equal-Weight | Overweight | 06 янв 2022 г. |
| JMP Securities | Market Outperform | 30 ноя 2021 г. | |
| JMP Securities | Market Outperform | Market Outperform | 19 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023
GlobeNewsWire
27 апр 2023 г. в 16:30
NEW YORK, April 27, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023 after the close of the US market.
Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023
GlobeNewsWire
01 мар 2023 г. в 16:30
NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market.
There's a Lot of Upside For Emerging Gene-Editing Companies
MarketBeat
21 февр 2023 г. в 09:16
Gene editing may be a relatively new industry, but it already has a lot of promise, especially for savvy biotech investors. Several gene editing companies have notable upsides, meaning that no matter how good or bad they might be doing right now, there is likely much more to come.
CLLS Stock: 23.01% Drop Explaination
Pulse2
05 февр 2023 г. в 00:25
The stock price of Cellectis SA (NASDAQ: CLLS) fell by 23.01% in the most recent trading session. This is why.
7 CRISPR Stocks With the Best Long-Term Potential
InvestorPlace
30 янв 2023 г. в 19:10
CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.